Health care stocks were flat to lower pre-bell Monday, with the Health Care Select Sector SPDR Fund (XLV) inactive and the iShares Biotechnology ETF (IBB) down 0.2%.
Argenx (ARGX) stock was nearly 4% higher after the company said a phase 3 study of its drug Vyvgart met its primary endpoint in treating patients with AChR-Ab seronegative generalized myasthenia gravis, an autoimmune disease.
Axogen (AXGN) shares were down more than 10% after the company said the US Food and Drug Administration has extended the review deadline for its marketing application for the Avance Nerve Graft by three months.
BeOne Medicines (ONC) shares were up more than 2% after the company said it has agreed to sell its royalty rights, excluding China, on Amgen's (AMGN) lung cancer drug, Imdelltra, to Royalty Pharma (RPRX) for up to $950 million.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.